Individualized medicine enabled by genomics in Saudi Arabia
- 4.5k Downloads
The biomedical research sector in Saudi Arabia has recently received special attention from the government, which is currently supporting research aimed at improving the understanding and treatment of common diseases afflicting Saudi Arabian society. To build capacity for research and training, a number of centres of excellence were established in different areas of the country. Among these, is the Centre of Excellence in Genomic Medicine Research (CEGMR) at King Abdulaziz University, Jeddah, with its internationally ranked and highly productive team performing translational research in the area of individualized medicine. Here, we present a panorama of the recent trends in different areas of biomedical research in Saudi Arabia drawing from our vision of where genomics will have maximal impact in the Kingdom of Saudi Arabia. We describe advances in a number of research areas including; congenital malformations, infertility, consanguinity and pre-implantation genetic diagnosis, cancer and genomic classifications in Saudi Arabia, epigenetic explanations of idiopathic disease, and pharmacogenomics and personalized medicine. We conclude that CEGMR will continue to play a pivotal role in advances in the field of genomics and research in this area is facing a number of challenges including generating high quality control data from Saudi population and policies for using these data need to comply with the international set up.
KeywordsGenetic Counselling Congenital Malformation Assisted Reproductive Technology Congenital Heart Defect Gulf Cooperation Council
List of abbreviations
Adverse Drug Reactions
Acute Lymphoblastic Leukaemia
Advanced Premarital Screening
Assisted Reproductive Technologies
Average Standardized Rates
Centre of Excellence in Genomic Medicine Research
Comparative Genomic Hybridization
Congenital Heart Defects
CpG Island Methylator Phenotype
Centre of Innovation for Personalized Medicine
Central Nervous System
Catalogue of Transmission Genetics in Arabs
Duchene Muscular Dystrophy
Drug Metabolizing Enzyme
elective Single Embryo Transfer
Food and Drug Administration
Gulf Cooperation Council
Genome Wide Association Studies
human Embryonic Stem Cells
International Agency for Research on Cancer
- IVF in vitro
King Abdullah City for Science and Technology
King Abdulaziz University
- KFSH & RC
King Faisal Specialist Hospital & Research Centre
Kingdom of Saudi Arabia
Ministry Of Health
Next Generation Sequencing
Non-Steroidal Anti-Inflammatory Drugs
Pre-implantation Genetic Diagnosis
Serious Adverse Drug Reactions
Sickle Cell Disease
Saudi Human Genome Program
Single Nucleotide Polymorphisms
Type 2 Diabetes Mellitus
In order to apply 21st century solutions in biomedical health research, at least three foundational genomic research initiatives are under way in the Gulf Cooperation Council (GCC), which include Kingdom of Saudi Arabia, Qatar, Oman, Bahrain, Kuwait and United Arab Emirates. These initiatives include, the catalogue of transmission genetics in Arabs (CTGA)  hosted by the Centre for Arab Genomic Studies in the United Arab Emirates, the Qatar Biobank Initiative  and the Saudi human genome program (SHGP) .
Established in 2003, the main purpose of the CTGA is to increase public and academic awareness for early diagnosis of genetic diseases in the Pan Arab population and to translate scientific knowledge into individualized medical treatment and management programs. As of January 2014, the CTGA online database curates over 1,000 disease phenotypes with a focus on the epidemiology in the Arab world, and it also maintains a record of nearly 250 associated disease loci. Many of the disease phenotypes studied are either more frequent (such as G6PD deficiency) or are regionally endemic, restricted to certain tribal communities or even unique to consanguine families. Consanguinity, which is a main feature of the traditional Arabic culture (see below), leads to an increase of homozygosity for autosomal recessive genetic diseases which, from the perspective of research, can serve as an important repository for phenotype-genotype association studies . The Qatar BioBank was initiated in 2010 aiming to take biosamples from Qatari population into repository to investigate diseases common to the domestic population . Its ambitious goal is to serve as a driver for biomedical research inside and outside of Qatar. The SHGP intends to sequence the exomes and/or genomes of 100,000 Saudis within a period of five years taking advantage of the feasibility of next generation sequencing (NGS). In one of the large investments, NGS utilizing the Ion Proton technology (LifeTechnologies) has been allocated to the core facility of the SHGP in the capital Riyadh in addition to 15 planned satellite facilities across the Kingdom covering a substantial part of the 30 million nation’s populated areas. The satellites are established as collaborating institutions with self-adopted timelines and projects, which are led by on-site researchers independently from the SHGP headquarter.
Using the new genomic data, the SHGP is aiming to investigate a number of diseases, which are common or endemic in the country and have a strong genetic component such as diabetes, deafness, cardiovascular disease, neurodegeneration, cancer and inherited and Mendelian disorders (discussed below). Translational research aspects of this project include genetic counselling and in some instances further genetic testing of families where the underlying genetic mutations have been identified. For example, a number of genetic counselling services for inherited disorders like the pre-marital screening and genetic counselling program in Saudi Arabia for hemoglobinopathies and viral infections have been implemented . Developing applications in pharmacogenomics research and personalized medicine are prospective objectives that may also arise from the SHGP. In addition, the aggregate genetic information offers the opportunity to perform genome wide association studies (GWAS) in a new dimensional scale. Such studies may shed light upon a number of polymorphic traits that are associated with certain diseases and are suspected to add to their penetrance which may gain special importance for endemic conditions like body mass index and obesity , or for acute diseases like cancer .
I. Congenital malformations in Saudi Arabia
Congenital malformations are identified as physical irreversible alterations induced during embryo formation that can be grouped into five categories: (1) single-gene anomalies, (2) chromosomal abnormalities, (3) maternal illness conditions during early pregnancy, (4) environmental and genetic inducers (e.g., teratogens), and (5) unknown causes, which account for ~50% of congenital malformations .
Due to strong economic stability, obesity in Gulf countries in general and in Saudi Arabia and Kuwait in particular has become a high risk factor and a serious problem that reflects negatively on the these societies . According to the Saudi Arabian national nutrition survey issued in 2007, the prevalence of obesity among women is 23.6% compared to 14.2% in men . It has been reported that a mother’s body mass index of more than 30 is a predictor of a number of congenital malformations including cardiac, nervous system, facial and genitourinary tract defects . Environmental factors and metabolic disorders are believed to induce congenital infections with toxoplasmosis, and cytomegalovirus that in turn result in inducing a number of congenital malformations including; microcephaly, seizures and intracranial calcification [35, 36].
Different genomic research approaches to elucidate the causes of congenital anomalies in Saudi Arabia have recently begun to gain more attention. For example, a multi-level technology approach was used to unravel the molecular network that lead to cryptorchidism . Comparative genomic hybridization (CGH) was also used to analyse chromosome microdeletions that caused upper limbs disabilities , and exome sequencing led to the identification of the ADAMTS18 gene to be involved in eye development .
Despite a recommendation to launch a national screening program for congenital anomalies in 1997 , there remains a real need for a primary national prevention program. We believe this type of program should be congruent with an awareness program of the genetic and epigenetic causes of the birth defects in Saudi Arabia. There is support for the implementation of an extensive pre-marital and pre-implantation screening program, in addition to establishing a national database for congenital anomalies, and by offering genetic counselling when birth defects occur [39, 40]. Recently, King Faisal Specialist Hospital & Research Centre (KFSH & RC) in Riyadh launched a technical database core facility that aims to maintain database registries of a number of diseases and congenital defects in order to facilitate clinical and research domains in Saudi Arabia (http://rc.kfshrc.edu.sa/besc/sections/tdbcf/OurProjects.html). Among these registries are; new-born screening and biochemical genetics (http://nlnbs.kfshrc.edu.sa), cleft lip/palate and craniofacial anomalies (http://rc.kfshrc.edu.sa/bssc/clcpr_new/buttons/New_Site.htm), congenital heart defects (http://rc.kfshrc.edu.sa/chd_program/) and neural tube defects (http://rc.kfshrc.edu.sa/ntd/). Establishing similar regional initiatives connected to a central database facility would reveal the most accurate data on congenital malformations in Saudi Arabia.
At CEGMR, a number of research initiatives are already in place to screen and investigate the causes of congenital malformations in Saudi Arabia. Among these initiatives are KACST’s recently funded projects to apply microarray based CGH approach to unravel genome defects in the congenital heart diseases and another to screen and diagnose the developmental delay as well as other congenital malformations. In addition, CEGMR established a collaboration with the Environmental Sciences Department at KAU to analyse changes in gene expression profiling using array CGH, RNA-Seq and whole exome sequencing during early embryonic development that could be induced by air particulate pollution and pesticides.
II. Infertility and pre-implantation genetic diagnosis (PGD)
Infertility is a condition manifested by the biological incapacity of a couple to achieve a clinical pregnancy after at least one year of regular unprotected sexual intercourse . The prevalence of this disease continues to rise and affects about 1 out of 6 couples in Saudi Arabia and worldwide [42, 43]. Such infertility rates vary largely among countries and patient age . The most common factors that could explain this severe decline in fertility are reproductive aging through the postponement of marriages, lifestyle, nutrition, the quality of health care services, and decrease in the child-seeking behaviour [45, 46, 47]. These factors are mainly due to the maternal age and to a lesser extent the paternal factors that could correlate with increased rates of gametes’ chromosome cohesion and therefore higher aneuploidy and chromosomal abnormalities in blastocysts [48, 49, 50].
There is an increase in the number of couples seeking infertility treatment services in assisted reproductive technologies (ART) clinics to help them to procreate. Despite valuable ART advantages, a remaining challenge is to increase qualitatively and quantitatively the in vitro fertilization (IVF) outcomes and reduce health care costs for both the mother and the offspring [51, 52]. The gametes’ (spermatozoa and oocyte) quality has been recognized as the major limiting step and is therefore the target of numerous studies to improve their selection procedure [53, 54, 55, 56], in order to make the elective single embryo transfer (eSET) procedure more effective [57, 58]. Chromosomal and some genetic mutations have been reported to underlie many of the challenges for obtaining successful embryo implantation and subsequent delivery of healthy babies [59, 60, 61].
An overview of the main genetic and chromosomal disorder in Saudi Arabia and their relationship with consanguinity. (++): High correlation; (+): Positive correlation; ND: Not Determined.
Disease prevalence* (%)
Congenital Malformations or birth defects
Polygenic and/or multifactorial
Congenital heart disease (CHD)
Duchene muscular dystrophy (DMD)
Hereditary Recessive deafness
Hereditary blindness & visual impairment
110 to 237
0.5 to 2.6
Sickle Cell Disease (SCD)
9 to 14.5
7.7 to 20
Given the challenges of high rates of consanguinity and disease in the Middle East and in Saudi Arabia, the Saudi ministry of health (MOH) decided in 2004 to make the premarital testing compulsory [5, 62]. Such premarital examination includes mainly the basic blood tests, the hemoglobinopathies screening (Thalassemia & Sickle Cell Anaemia) and virology assays (Hepatitis B and C; AIDS). Despite these important measurements, PGD is still restricted to only few IVF clinics and it is the opinion of the authors that the level of awareness about infertility problems and genetic diseases needs to be given more attention especially in regions with high consanguinity as well as in rural and tribal areas. Investment in training and staffing in genetic counselling will also then be required.
The CEGMR aims to play a leading role in PGD by building translational research capacity. CEGMR is currently working in collaboration with KACST Centre of Innovation for Personalized Medicine (CIPM), Jeddah at KAU; the latter is being involved in delivering service through PGD screening for the larger Saudi population. CEGMR is currently developing new infertility screening methods using a specific panel of biomarkers with the primary aim being to reduce the comparatively high recurrence of abortions. For examples, new advances in technology have allowed the transfer of two embryos to the eSET preventing multiple pregnancies, which can disadvantage both the mother and the baby . Similarly, a new project was recently initiated to establish an advanced premarital screening (APS) using state-of-the-art approaches with higher coverage (number of diseases) and accuracy. Once validated, such APS package will be presented to the MOH for consideration as an improvement of the existing test using advanced high throughput technologies.
Together, fertility and PGD screening programs as well as the APS package are excellent tools that are on line with the latest advances in the reproductive and developmental medicine field worldwide and are expected to significantly enhance the efficiency of both infertility diagnosis and treatment [64, 65, 66]. They will also facilitate detection and prevention of the transfer of most of the inherited disorders to the upcoming generations.
III. Cancer and genomic classifications in Saudi Arabia
IV. Epigenetic explanations of idiopathic disease
A marked feature of cancer in the Kingdom of Saudi Arabia is the relatively young age of onset. The most common cancer type in Saudi Arabia is breast cancer comprising more than 16% of the cases seen at the largest oncology referral centre in the Kingdom, KFSH & RC . Most of the affected females are below 50 years of age , which differs from Western countries where the age of onset is later . Colon cancer is the most cancer type affecting Saudi males and here too the age of onset (40-65 years)  is less than seen in the west . The reason for such age discrepancy is not entirely known. However, factors such as the early age of menarche (<12 years) and the use of exogenous progesterone and oestrogens could be suspected in the case of breast cancer . The relatively young age of onset in this population could be explained by the interplay between common genetic susceptibility background substantiated by increased consanguinity and epigenetic aberrations. These factors are thought to be caused by shifts in life style being experienced in Saudi Arabia and in the Middle East in general in the past few decades. Similar life-style shifts are also seen in emerging economies such as India. Similar to Saudi Arabia, there is an increasing number of younger patients diagnosed with cancer every year in India . The presence of a common genetic susceptibility factor(s) amongst Saudis is unknown. Interestingly, no significant associations of BRCA1 and BRCA2 mutations or SNP have been found in Saudi breast cancer cohorts [96, 97]. However, there is an ongoing study to elucidate this further at CEGMR using high throughput technologies including Ion Torrent whole genome sequencing. In addition, our exome sequencing efforts of familial breast cancer cases have yet to reveal a common gene or mutation in the samples so far analysed . Interestingly, every family sequenced thus far has a different underlying putative defective gene(s) precluding our ability to provide supporting evidence for the hypothesis that suggests the presence of a consanguinity-driven common genetic haplotype associated with increased susceptibility to breast cancer . A more defined role for a “cancer susceptibility genome” will be determined following the conclusion of the SHGP project .
Epigenetics could therefore play a major role in the shift towards a younger age of onset. Life-style changes such as sleep and shift work patterns, diet and exercise can affect the genome in several ways and need to be considered. The circadian rhythm, mediated through an intricate network of transcriptional and post-translational mediators is necessary for maintaining a healthy homeostasis [100, 101, 102]. When the circadian rhythm is disrupted through sleep deprivation, global changes in gene expression can occur altering cellular behaviour. Methylation is a key mechanism for altering gene expression in response to sleep deprivation, such as what happens to the brain function . The pleiotropic melatonin is the main sensor for light and it has cancer-protective effects through several mechanisms, including regulating estrogen pathway . Interestingly, we have identified frequent hypermethylation of the melatonin receptor, MTNR1B, in a fraction of our cohort of breast cancer cases (35%) with significant association with histological grade I . Such a result is intriguing and could implicate the epigenetic deregulation of key components of the circadian clock, which in turn, could potentiate cancer at an early age [100, 101].
Sleep deprivation is not the only suspect behind the age shift observed. Aberrant metabolism is also likely to play a role. The incidence rates of the metabolic syndrome (obesity, high blood pressure, elevated fasting glucose levels, elevated cholesterol levels) in Saudi Arabia are reported to be among the highest in the world . There is also emerging evidence of metabolic syndromes contributing to the increasing rates and age shift of cancer in Saudi Arabia. Our genome-wide methylation analysis of breast cancer has identified a role for the KLOTHO-FGF19-FGF23-FGFR4 signaling axis. FGF19 expression is elevated and is associated with a significantly shorter life expectancy of breast cancer patients of Saudi and Libyan descent . The upregulation of FGF19 expression is coupled with high FGF23 and FGFR4 expression and frequent methylation of KLOTHO in the same cohort (Unpublished data). While a role for FGFR4 has been previously shown [108, 109], implicating the metabolic hormones FGF19, FGF23 and KLOTHO in cancer is equally intriguing; the emerging question being if dysregulation of these genes may be a direct cause of carcinogenesis or more generally a symptom of metabolic health, which in itself predisposes to cancer at a significantly younger age? More work is warranted to shed light on the role of this metabolic axis in cancer because of its potential as an actionable target for treatment [110, 111].
Other genes are inactivated by promoter hypermethylation. In colorectal cancer from Saudi Arabia, the methylation of the polycomb gene targets in the absence of CpG island methylator phenotype (CIMP) is a predictor of favourable prognosis . Interestingly, we have identified a group of older patients with no detectable methylation in the genes analysed and yet displayed aggressive tumours that led to a significantly lower disease-specific survival rates . The most frequent methylation event detected in breast cancer from Saudi cases is at the RASSF1A promoter, an event that is a potential predictor of poor prognosis . However, the methylation frequency of other genes analysed in that study was lower than reported elsewhere, especially in the case of Estrogen Receptor-1 (ESR1) and Cadherin-1 (CDH1) methylation . This could be attributed to the relatively early age of onset for the patients analysed, or to the presence of regional and ethnic-specific differences in gene regulation in breast cancer. BRCA1 methylation in blood from breast cancer patients could provide a potential mechanism for cancer susceptibility in the Saudi population and offer a promising tool for the detection of cancer predisposition . Amplification of TNRC9, a common event in breast cancer from the MENA region, can directly result in the epigenetic silencing of BRCA1 expression . Incidentally, SNPs in the TNRC9 locus have been shown to be significantly associated with breast cancer .
Other epigenetic lesions underlying cancer in Saudi Arabia could exist. Differential expression of miRNAs including hsa-mir-146a2, hsa-mir-196a2 and hsa-mir-499 are detected in peripheral blood of breast cancer patients . Furthermore, polymorphisms identified in those miRNAs have been found to be significantly associated with breast cancer susceptibility . A similar effect is observed in risk modification for prostate cancer in northern Indian populations . Polymorphisms in hsa-mir-196a has been shown to be associated with increased risk for nasopharyngeal carcinoma in Chinese patients , and with increased risk for non-small cell lung carcinoma in the Korean population . Conversely, these genetic variants do not seem to influence breast cancer risk or age of onset in German or Italian populations .
V. Pharmacogenomics and personalized medicine
Pharmacogenomics (PGx) is the study of the role of genetic polymorphisms in drug response [122, 123]. PGx is a rapidly evolving field in particular due to the rapid advances in genotyping platforms and NGS technologies to scan the genome at increasing levels of resolution . The interface of PGx and complex diseases including various types of cancers, understanding and managing serious adverse drug reactions (SADRs), and public health pharmacogenetics, are the major areas of investigation at CEGMR and elsewhere [124, 125].
The potential opportunities emerging from PGx include, but not limited to, the prediction of personalized response to drugs, tailor-made prescriptions, reducing adverse drug reactions (ADRs), increasing the efficacy and reducing the toxicity of drugs, developing more robust and safer vaccines, monitoring and screening of specific diseases, as well as advancing research and development of novel drugs . Pharmacogenetics (PGt) is the study of single genes that have significant influence on clinically actionable drugs .
In the past two decades, several drugs were primarily withdrawn from the USA market due to ADRs [125, 127, 128]. The ADRs are broadly categorized into Type A and B reactions . Type A reactions are predictable, dose-dependent and constitute about 80% of ADRs [125, 127]. The hypotension with anti-hypertensive treatment and incidences of bleeding in patients treated with Warfarin are some of the examples of Type A ADRs [125, 127]. However, Type B reactions are termed as “idiosyncratic” or random ADRs observed mostly in genetically susceptible individuals . Moreover, Type B reactions may potentially lead to SADRs that require either temporary or prolonged hospitalization and in some instances permanent disability or are even fatal [125, 129]. Deciphering the genetic variations in populations , associated with Type B reactions using PGx strategies, could markedly reduce the healthcare budgets, promote drug discovery and the development of reliable and safer drugs [125, 129].
The Cytochrome P450 (CYP450) super-family consists of functionally diverse groups of drug detoxifying enzymes encoded by 57 genes and 5 pseudo genes, identified thus far, in the human genome [131, 132]. The CYP450 enzymes are chiefly expressed in liver and facilitate the metabolism of drugs, xenobiotics, toxic pollutants, steroids, vitamin D, cholesterol metabolism and bile synthesis, retinoic acid, arachidonic acid and eicosanoids [132, 133] by conjugating with functional groups and eventually removal from the body [132, 134, 135]. Members of the CYP450 super-family like CYP1, CYP2, and CYP3 are essential for the phase I metabolism of about 90% of all clinically applicable drugs [134, 135, 136]. The personalized variations in the expression of chief detoxifying CYP450 enzyme systems in humans, such as CYP1A2, CYP2C, CYP2D6, CYP2E1, CYP3A4 and CYP3A5, can influence the metabolism of a clinically relevant drug and the ADRs associated with its standard doses [124, 135, 136]. An array of factors such as the genetic polymorphisms, poor diet, endocrine dysregulation, epigenetic changes, acute and chronic liver diseases can critically influence the personalized variation in the expression of CYP450 system [135, 137]. Besides, the CYP450 clinical phenotypes are classified based on individuals’ ability to metabolize a particular drug as ultra-rapid metabolizers (UMs), Extensive Metabolizers (EMs), Intermediate Metabolizers (IMs) and poor metabolizers (PMs) [138, 139]. The PMs have two non-functional alleles that decrease the expression of a particular CYP450 enzyme ; IMs have one functional allele and one heterozygous null allele for a CYP450 enzyme . EMs have two functional homozygous alleles and may require higher concentrations of a therapeutic drug compared with IMs and PMs . UMs have two or more copies of a functional CYP450 gene and metabolize the drug substrates rapidly and always require higher concentrations of drugs to achieve good therapeutic outcomes .
Genetic polymorphisms of CYP450 superfamily of genes greatly influence the efficacy, safety and the clinical outcome of a drug treatment . CYP2D6 is one of most important CYP450 enzyme required for the metabolism of more than 30% of therapeutically relevant drugs, including antidepressants and antipsychotics [138, 139]. It is polymorphically expressed, and found to be absent in 1- 2% of Asians, 6 - 10% of Caucasians  and are classified as PMs [138, 139]. Over 25% of Ethiopians and 2% of Caucasians are classified as CYP2D6 UMs [138, 140]. In general, PMs of drugs have an increased risk of developing ADRs when compared to UMs and EMs. For example, codeine, a pro-drug, is converted to morphine by CYP2D6 enzyme to exert its analgesic properties . Therefore, the efficacy of codeine was significantly reduced in individuals with CYP2D6 PMs . On the other hand, the efficacy of codeine was markedly increased in CYP2D6 IMs and CYP2D6 UMs leading to drug toxicity in some individuals .
CYP2C subfamily of enzymes metabolizes about 20% of clinically relevant drugs including non-steroidal anti-inflammatory drugs (NSAIDs), oral anticoagulants and oral anti-diabetic agents such as tolbutamide, glibenclamide, glimepiride and glipizide [141, 142, 143]. To date, more than 57 alleles of CYP2C9 have been reported  amongst which CYP2C9*2 and CYP2C9*3 alleles are the most prevalent in Caucasian as well as Asian populations and individuals carrying these polymorphisms exhibit reduced CYP2C9 activity . An association was established between reduced expression of CYP2C9 and higher risk of bleeding episodes and upper-gastrointestinal (GI) bleeding in Warfarin-treated patients [136, 145]. The alleles of CYP2C9 namely, CYP2C9*2 and CYP2C9*3 are responsible for reduced CYP2C9 enzyme activity leading to increased anti-coagulation . These patients should be administered with lower dose of Warfarin to attain effective anti-coagulation, and diminish the possibility of bleeding episodes [136, 145, 146].
In December 2004, the United States food and drug administration (FDA) approved the drug metabolizing enzyme (DME) genotyping system from Roche named as AmpliChipTMCYP450 array . The AmpliChip P450 array is used in Affymetrix GeneChip microarray instrumentation system to identify a patient’s CYP2D6 and CYP2C19 genotypes from genomic DNA isolated from whole blood sample . Based on the CYP450 genetic test results, clinical evaluation and other lab tests as a reference, the clinician designs personalized treatment options for patients to minimize the risk of ADRs and sub-optimal dose response . It was estimated that about 25% of all prescribed drugs in the USA contain PGx labelling [136, 153], for example, the anti-coagulant Warfarin with PGx indications of CYP2C9 genotype specific dosing [136, 154]. The FDA has published a table of PGx biomarkers in drug labelling of about 135 therapeutically relevant drugs in the market [26, 155].
Though the advancing technologies in genomics and bioinformatics rapidly steer PGx towards personalized therapy for patients in clinics, PGx tests are currently limited to evaluate the safety and therapeutic efficacy of drugs for thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement, human immunodeficiency virus, chronic myeloid leukaemia and gastrointestinal stromal tumours, ALL, colon, breast and lung cancers .
At present, the key challenges of personalized medicine include; achieving the goal of $1000 genome , increasing the speed of genome or exome sequencing by yet to be developed technologies , and making these platforms user friendly. Moreover, establishing dynamic PGx tools and databases [158, 159, 160], training physicians to apply PGx results to formulate preventive and personalized healthcare , and establishing privacy rules will be required to further the translational science [122, 156]. At CEGMR, we are currently in the process of establishing custom-built PGx tools and databases as well as evaluating the PGx and toxicogenomics of several drugs used for the treatment of diseases afflicting Saudi population. Last, but perhaps most important, will be to, establish proper allele frequencies in populations from Saudi regions and others from across the globe [123, 156].
Discussion and summary
All of the investments in equipment in genomics infrastructure, and informatics at CEGMR aid in generating fundamental knowledge to facilitate effective decision making for individuals and families. Our primary objective is to generate the highest quality genomic data from patients and relevant family and population controls to enable opportunity for point-of-care, as well as iterative decision making based on the comparative medical data available. The advantage in the Saudi system is centralized medical care and shared experiences in families, which will also enable genome-based discoveries and treatments among families, physicians, and researchers .
We also recognize the importance of thoughtful deliberation on issues of societal awareness about consanguinity, infertility, and stigma associated with some genetic disorders and malformations. Therefore, the authority has launched several education and outreach programs in hospitals and schools . CEGMR will continue to launch proactive communication plans with stakeholders such as government, media, children with disabilities, charitable associations, and other society representatives. Coupled with research, will also be newer ethical consenting processes that are particularly conscience of the vast array of genetic findings (and their implications) that arise from genome scanning . Much of the data will be amenable to confidentiality, protection and control using an informatics-based approach [165, 166]. However, there remains an urgent need in Saudi Arabia for up to date policies that comply with international standards, which implement strict control and protection of privacy and public release of bio-specimens and data [166, 167, 168]. CEGMR will also continue to develop and implement new algorithms and databases enabling iterative dynamic interpretations of data in personalized health decision making [169, 170, 171].
Other considerations relevant to translational medicine in the Saudi system include making reproductive health and ART more accessible and affordable for the average Saudi citizen so this approach can further ease the current staggering impact congenital malformations and genetic disease are having on the health care system . We believe that there is a need for a strategic plan to recommend the PGD for patients with hereditary genetic disorders and receiving IVF services in the Kingdom. There also needs to be proactive and clear policies on the use of the human Embryonic Stem Cells (hESCs) and these should be easily accessed by all who are interested in the human stem cells research.
The authors disclose no competing financial interests.
We would like to thank KACST for funding and supporting research in Saudi Arabia from which many results are reported in this review. MAE is funded by KACST Project Codes: 13-BIO789-03, 13-BIO669-03 and 13-CIPM-1.PP is funded by KACST Strategic Project Codes: 12-BIO2719-03 and 12-BIO2267-03. FA is funded by KACST Strategic Project Codes: 09-BIO-693-03.
Publication charges for this article were funded by the Center of Excellence in Genomic Medicine Research (CEGMR), King Abdulaziz University, Jeddah, 21589, Kingdom of Saudi Arabia.
This article has been published as part of BMC Medical Genomics Volume 8 Supplement 1, 2015: Selected articles from the 2nd International Genomic Medical Conference (IGMC 2013): Medical Genomics. The full contents of the supplement are available online at http://www.biomedcentral.com/bmcmedgenomics/supplements/8/S1
- 2.Qatar Biobank for Medical Research. [http://www.qatarbiobank.org.qa/]
- 3.Saudi Human Genome Program. [http://rc.kfshrc.edu.sa/sgp/]
- 6.Ng SW, Zaghloul S, Ali HI, Harrison G, Popkin BM: The prevalence and trends of overweight, obesity and nutrition-related non-communicable diseases in the Arabian Gulf States. Obesity reviews : an official journal of the International Association for the Study of Obesity. 2011, 12 (1): 1-13. 10.1111/j.1467-789X.2010.00750.x.Google Scholar
- 8.Scherer SW: Genomics is the medium for 21st century biology. Genome / National Research Council Canada = Genome / Conseil national de recherches Canada. 2012, 55 (10): v-Google Scholar
- 9.Sheridan E, Wright J, Small N, Corry PC, Oddie S, Whibley C, Petherick ES, Malik T, Pawson N, McKinney PA, et al: Risk factors for congenital anomaly in a multiethnic birth cohort: an analysis of the Born in Bradford study. Lancet. 2013, 382 (9901): 1350-1359. 10.1016/S0140-6736(13)61132-0.PubMedGoogle Scholar
- 14.Shoukri MM, Donner A, Dessouky NA, Subhani S, Al-Joufan M, Al-Omrani A, Al-Mohanna F, Al Halees ZY: Estimation of modified concordance ratio in sib-pairs: effect of consanguinity on the risk of congenital heart diseases. The international journal of biostatistics. 2010, 6 (1): Article 3Google Scholar
- 24.El-Awad Mel H, Sivasankaran S: Neural tube defects in Southwestern region of Saudi Arabia. Annals of Saudi medicine. 1992, 12 (5): 449-452.Google Scholar
- 32.Adnan Amin Alsulaimani AKA: Prevalence of congenital anomalies at high altitude area in saudi arabia. Saudi medical journal. 2010, 1 (3): 44-51.Google Scholar
- 33.Al-Othaimeen AI, Al-Nozha M, Osman AK: Obesity: an emerging problem in Saudi Arabia. Analysis of data from the National Nutrition Survey. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2007, 13 (2): 441-448.Google Scholar
- 34.Balaha MH, Ali WH, Al Aswad LH, Al Moghannum MS, Hashim I: Maternal obesity predict isolated birth defects in live births in Eastern Province of Saudi Arabia. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2012, 25 (7): 924-929. 10.3109/14767058.2011.600367.Google Scholar
- 35.Eyaid W, Al-Tassan RS, Al-Nouri DM: Intracranial calcifications, microcephaly, and seizure. If not congenital infection, what could it be?. Neurosciences. 2012, Riyadh, Saudi Arabia, 17 (3): 248-252.Google Scholar
- 40.Al-Odaib A: Saudi Newborn Screening (NBS) Program for Metabolic Diseases. 2003, Princ Salamn Centre for Disability Research, [http://www.pscdr.org.sa/en/research/projects/Pages/SaudiNewbornScreening[NBS]ProgramforMetabolicDiseases.aspx]Google Scholar
- 41.Zegers-Hochschild F, Adamson GD, de Mouzon J, Ishihara O, Mansour R, Nygren K, Sullivan E, van der Poel S: The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) Revised Glossary on ART Terminology, 2009. Hum Reprod. 2009, 24 (11): 2683-2687. 10.1093/humrep/dep343.PubMedGoogle Scholar
- 42.Mundi I: Saudi Arabia Demographics Profile. 2013, [http://www.indexmundicom/saudi_arabia/demographics_profilehtml]Google Scholar
- 43.Boivin J, Bunting L, Collins JA, Nygren KG: International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Human reproduction. 2007, Oxford, England, 22 (6): 1506-1512. 10.1093/humrep/dem046.Google Scholar
- 46.Buhling KJ, Grajecki D: The effect of micronutrient supplements on female fertility. Current opinion in obstetrics & gynecology. 2013, 25 (3): 173-180. 10.1097/GCO.0b013e3283609138.Google Scholar
- 48.Liu J, Wang W, Sun X, Liu L, Jin H, Li M, Witz C, Williams D, Griffith J, Skorupski J, et al: DNA microarray reveals that high proportions of human blastocysts from women of advanced maternal age are aneuploid and mosaic. Biology of reproduction. 2012, 87 (6): 148-10.1095/biolreprod.112.103192.PubMedGoogle Scholar
- 51.Okun N, Sierra S, Wilson RD, Audibert F, Brock JA, Campagnolo C, Carroll J, Cartier L, Chitayat D, Gagnon A, et al: Pregnancy outcomes after assisted human reproduction. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC. 2014, 36 (1): 64-83.PubMedGoogle Scholar
- 53.Esteves SC, Miyaoka R, Agarwal A: Sperm retrieval techniques for assisted reproduction. International braz j urol : official journal of the Brazilian Society of Urology. 2011, 37 (5): 570-583. 10.1590/S1677-55382011000500002.Google Scholar
- 55.Mehri S, Levi Setti PE, Greco K, Sakkas D, Martinez G, Patrizio P: Correlation between follicular diameters and flushing versus no flushing on oocyte maturity, fertilization rate and embryo quality. Journal of assisted reproduction and genetics. 2014, 31 (1): 73-77. 10.1007/s10815-013-0124-9.PubMedGoogle Scholar
- 56.Assidi M, Sirard M-A: Cumulus Cell Gene Expression as a Marker of Oocyte Quality. Oogenesis. Edited by: Coticchio G, Albertini DF, De Santis L. 2013, London: Springer, 231-252.Google Scholar
- 58.Straughen JK, Salihu HM, Keith L, Petrozzino J, Jones C: Obligatory versus elective single embryo transfer in in vitro fertilization. A population-based analysis of data from the U.K. Human Fertilisation and Embryology Authority. The Journal of reproductive medicine. 2013, 58 (3-4): 95-100.PubMedGoogle Scholar
- 61.Lo Giacco D, Chianese C, Sanchez-Curbelo J, Bassas L, Ruiz P, Rajmil O, Sarquella J, Vives A, Ruiz-Castane E, Oliva R, et al: Clinical relevance of Y-linked CNV screening in male infertility: new insights based on the 8-year experience of a diagnostic genetic laboratory. European journal of human genetics : EJHG. 2013Google Scholar
- 62.Ibrahim NK, Bashawri J, Al Bar H, Al Ahmadi J, Al Bar A, Qadi M, Milaat W, Feda H: Premarital Screening and Genetic Counseling program: knowledge, attitude, and satisfaction of attendees of governmental outpatient clinics in Jeddah. Journal of infection and public health. 2013, 6 (1): 41-54. 10.1016/j.jiph.2012.05.001.PubMedGoogle Scholar
- 64.Yuen RK, Merkoulovitch A, Macdonald JR, Vlasschaert M, Lo K, Grober E, Marshall CR, Jarvi KA, Kolomietz E, Scherer SW: Development of a high-resolution Y-chromosome microarray for improved male infertility diagnosis. Fertility and sterility. 2014Google Scholar
- 65.Nepomnyashchaya YN, Artemov AV, Roumiantsev SA, Roumyantsev AG, Zhavoronkov A: Non-invasive prenatal diagnostics of aneuploidy using next-generation DNA sequencing technologies, and clinical considerations. Clinical chemistry and laboratory medicine : CCLM / FESCC. 2013, 51 (6): 1141-1154.Google Scholar
- 66.Colls P, Escudero T, Fischer J, Cekleniak NA, Ben-Ozer S, Meyer B, Damien M, Grifo JA, Hershlag A, Munne S: Validation of array comparative genome hybridization for diagnosis of translocations in preimplantation human embryos. Reproductive biomedicine online. 2012, 24 (6): 621-629. 10.1016/j.rbmo.2012.02.006.PubMedGoogle Scholar
- 67.Al-Hamdan N, Ravichandran K, Al-Sayyad J, Al-Lawati J, Khazal Z, Al-Khateeb F, Abdulwahab A, Al-Asfour A: Incidence of cancer in Gulf Cooperation Council countries, 1998-2001. Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit. 2009, 15 (3): 600-611.Google Scholar
- 68.10-Year Cancer Incidence Among Nationals of the GCC States 1998-2007. [http://www.moh.gov.bh/pdf/publications/GCC%20Cancer%20Incidence%202011.pdf]
- 69.World Health Organization, Regional Office for the Eastern Mediterranean, Cancer registration in the Region. [http://www.emro.who.int/noncommunicable-diseases/information-resources/cancer-registration.html]
- 70.Cancer Incidence Report in Saudi Arabia 2009. [http://scr.clearvision.com.sa/]
- 71.GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. [http://globocan.iarc.fr]
- 72.SEER Cancer Statistics Review, 1975-2010. SEER web site. Edited by: Howlader N NA, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. 2013, National Cancer Institute. Bethesda, MD, November 2012 SEER data submissionGoogle Scholar
- 73.Al-Zahrani AS, Ravichandran K: Epidemiology of thyroid cancer: a review with special reference to Gulf Cooperation Council (GCC) states. The Gulf journal of oncology. 2007, 17-28. 2Google Scholar
- 75.Alghamidi IG, Hussain II, Alghamdi MS, El-Sheemy MA: The incidence rate of prostate cancer in Saudi Arabia: an observational descriptive epidemiological analysis of data from the Saudi Cancer Registry 2001-2008. Hematology/oncology and stem cell therapy. 2013Google Scholar
- 76.Elkum N, Dermime S, Ajarim D, Al-Zahrani A, Alsayed A, Tulbah A, Al Malik O, Alshabanah M, Ezzat A, Al-Tweigeri T: Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experience. BMC cancer. 2007, 7: 222-10.1186/1471-2407-7-222.PubMedPubMedCentralGoogle Scholar
- 79.Siraj AK, Al-Rasheed M, Ibrahim M, Siddiqui K, Al-Dayel F, Al-Sanea O, Uddin S, Al-Kuraya K: RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population. Journal of endocrinological investigation. 2008, 31 (10): 893-899. 10.1007/BF03346438.PubMedGoogle Scholar
- 80.Siraj AK, Ibrahim M, Al-Rasheed M, Abubaker J, Bu R, Siddiqui SU, Al-Dayel F, Al-Sanea O, Al-Nuaim A, Uddin S, et al: Polymorphisms of selected xenobiotic genes contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population. BMC medical genetics. 2008, 9: 61-PubMedPubMedCentralGoogle Scholar
- 82.Al-Sudairy R, Al-Nasser A, Alsultan A, Al Ahmari A, Abosoudah I, Al-Hayek R, Al-Harbi T, Al-Manjomi F, Al-Harbi M, Al-Ghamdi H, et al: Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia in Saudi Arabia: a multi-institutional retrospective national collaborative study. Pediatric blood & cancer. 2014, 61 (1): 74-80. 10.1002/pbc.24584.Google Scholar
- 84.AlShemmari SH, Ameen RM, Sajnani KP: Extranodal lymphoma: a comparative study. Hematology. 2008, Amsterdam, Netherlands, 13 (3): 163-169. 10.1179/102453308X316149.Google Scholar
- 86.Hussain AR, Uddin S, Ahmed M, Al-Dayel F, Bavi PP, Al-Kuraya KS: Phosphorylated IkappaBalpha predicts poor prognosis in activated B-cell lymphoma and its inhibition with thymoquinone induces apoptosis via ROS release. PloS one. 2013, 8 (3): e60540-10.1371/journal.pone.0060540.PubMedPubMedCentralGoogle Scholar
- 89.Uddin S, Hussain AR, Ahmed M, Bu R, Ahmed SO, Ajarim D, Al-Dayel F, Bavi P, Al-Kuraya KS: Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-cell lymphoma. Molecular cancer therapeutics. 2010, 9 (5): 1244-1255. 10.1158/1535-7163.MCT-09-1061.PubMedGoogle Scholar
- 91.Siegel R, Naishadham D, Jemal A: Cancer statistics. CA: A Cancer J Clinicians. 2013, 63 (1): 11-30. 10.3322/caac.21166.Google Scholar
- 92.Mehmood A, Te OB, Urcia JC, Khan A: Tumor Registry Annual Report. 2011, Kingdom of Saudi Arabia: King Faisal Specialist Hospital & Research CenterGoogle Scholar
- 93.CancerStats. [http://www.cancerresearchuk.org/cancer-info/cancerstats/]
- 94.Al-Qutub ST, Al-Raddadi RM, Bin Sadiq BM, Sait W, Al-Gahmi A, Al-Amoudi S: Potential breast cancer risk factors among Saudi women aged 19-50 years in Jeddah: a case-control study. The Journal of the Egyptian Public Health Association. 2013, 88 (3): 165-170. 10.1097/01.EPX.0000435728.60811.bd.PubMedGoogle Scholar
- 95.PINK Indian Statistics. [http://www.breastcancerindia.net/bc/statistics/stati.htm]
- 96.El-Harith el HA, Abdel-Hadi MS, Steinmann D, Dork T: BRCA1 and BRCA2 mutations in breast cancer patients from Saudi Arabia. Saudi medical journal. 2002, 23 (6): 700-704.Google Scholar
- 97.Hasan TN, Shafi G, Syed NA, Alsaif MA, Alsaif AA, Alshatwi AA: Lack of association of BRCA1 and BRCA2 variants with breast cancer in an ethnic population of Saudi Arabia, an emerging high-risk area. Asian Pacific journal of cancer prevention : APJCP. 2013, 14 (10): 5671-5674. 10.7314/APJCP.2013.14.10.5671.PubMedGoogle Scholar
- 98.Hussein S, Merdad A, Al-Maghrabi J, Gari M, Al-Thubaiti F, Hussein I, Chaudhary A, Abuzenadah A, Tashkandi H, Al-Khayyat S, et al: Detection of rare single nucleotide variants affecting genes in the DNA repair pathways in hereditary breast cancer. BMC Genomics. 2014, 15 (Suppl 2): P20-10.1186/1471-2164-15-S2-P20.PubMedCentralGoogle Scholar
- 99.Saudi Human Genome Program. [http://rc.kfshrc.edu.sa/sgp/]
- 102.Zelinski EL, Deibel SH, McDonald RJ: The trouble with circadian clock dysfunction: Multiple deleterious effects on the brain and body. Neuroscience and biobehavioral reviews. 2014, 40c: 80-101.Google Scholar
- 103.Massart R, Freyburger M, Suderman M, Paquet J, El Helou J, Belanger-Nelson E, Rachalski A, Koumar OC, Carrier J, Szyf M, et al: The genome-wide landscape of DNA methylation and hydroxymethylation in response to sleep deprivation impacts on synaptic plasticity genes. Translational psychiatry. 2014, 4: e347-10.1038/tp.2013.120.PubMedPubMedCentralGoogle Scholar
- 105.Shylu Mathew AM, Jaudah Al-Maghrabi, Ashraf Dallol: Identification of frequent MTNR1B methylation in breast cancer following the application of high-throughput methylome analysis. BMC Genomics. 2014, 15 (Supplement 2):Google Scholar
- 106.Al-Daghri NM, Khan N, Alkharfy KM, Al-Attas OS, Alokail MS, Alfawaz HA, Alothman A, Vanhoutte PM: Selected dietary nutrients and the prevalence of metabolic syndrome in adult males and females in Saudi Arabia: a pilot study. Nutrients. 2013, 5 (11): 4587-4604. 10.3390/nu5114587.PubMedPubMedCentralGoogle Scholar
- 107.Buhmeida A, Dallol A, Merdad A, Al-Maghrabi J, Gari MA, Abu-Elmagd MM, Chaudhary AG, Abuzenadah AM, Nedjadi T, Ermiah E, et al: High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013Google Scholar
- 108.Dutra RL, de Carvalho MB, dos Santos M, Mercante AC, Gazito D, de Cicco R, Group G, Tajara EH, Louro ID, da Silva AMA: FGFR4 Profile as a Prognostic Marker in Squamous Cell Carcinoma of the Mouth and Oropharynx. PloS one. 2012, 7 (11):Google Scholar
- 109.Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, et al: Identification of FGFR4 as a Potential Therapeutic Target for Advanced-Stage High-Grade Serous Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013, 19 (4): 809-820. 10.1158/1078-0432.CCR-12-2736.Google Scholar
- 110.Luo Y, Yang C, Lu W, Xie R, Jin C, Huang P, Wang F, McKeehan WL: Metabolic Regulator ?Klotho Interacts with Fibroblast Growth Factor Receptor 4 (FGFR4) to Induce Apoptosis and Inhibit Tumor Cell Proliferation*. The Journal of Biological Chemistry. 2010, 285 (39): 30069-30078. 10.1074/jbc.M110.148288.PubMedPubMedCentralGoogle Scholar
- 112.Dallol A, Al-Maghrabi J, Buhmeida A, Gari MA, Chaudhary AG, Schulten HJ, Abuzenadah AM, Al-Ahwal MS, Sibiany A, Al-Qahtani MH: Methylation of the polycomb group target genes is a possible biomarker for favorable prognosis in colorectal cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012, 21 (11): 2069-2075. 10.1158/1055-9965.EPI-12-0755.Google Scholar
- 113.Buhmeida A, Merdad A, Al-Maghrabi J, Al-Thobaiti F, Ata M, Bugis A, Syrjanen K, Abuzenadah A, Chaudhary A, Gari M, et al: RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency. Anticancer research. 2011, 31 (9): 2975-2981.PubMedGoogle Scholar
- 116.Shan J, Mahfoudh W, Dsouza SP, Hassen E, Bouaouina N, Abdelhak S, Benhadjayed A, Memmi H, Mathew RA, Aigha II, et al: Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians. Breast cancer research and treatment. 2012, 135 (3): 715-724. 10.1007/s10549-012-2202-6.PubMedPubMedCentralGoogle Scholar
- 119.Li P, Yan H, Zhang H, Yu L, Wang Z, Zhai Y, Xia X, Zhang J, Zhang Y, Ma F, et al: A Functional Polymorphism in MIR196A2 Is Associated with Risk and Progression of Nasopharyngeal Carcinoma in the Chinese Population. Genetic testing and molecular biomarkers. 2014, 18 (3): 149-155. 10.1089/gtmb.2013.0400.PubMedGoogle Scholar
- 120.Hong YS, Kang HJ, Kwak JY, Park BL, You CH, Kim YM, Kim H: Association between microRNA196a2 rs11614913 genotypes and the risk of non-small cell lung cancer in Korean population. Journal of preventive medicine and public health = Yebang Uihakhoe chi. 2011, 44 (3): 125-130. 10.3961/jpmph.2011.44.3.125.PubMedGoogle Scholar
- 121.Catucci I, Yang R, Verderio P, Pizzamiglio S, Heesen L, Hemminki K, Sutter C, Wappenschmidt B, Dick M, Arnold N, et al: Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases. Human mutation. 2010, 31 (1): E1052-1057. 10.1002/humu.21141.PubMedGoogle Scholar
- 129.Severino G, Del Zompo M: Adverse drug reactions: role of pharmacogenomics. Pharmacological research : the official journal of the Italian Pharmacological Society. 2004, 49 (4): 363-373. 10.1016/j.phrs.2003.05.003.Google Scholar
- 131.Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, et al: The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA and cell biology. 1993, 12 (1): 1-51. 10.1089/dna.1993.12.1.PubMedGoogle Scholar
- 133.Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW: Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics. 2004, 14 (1): 1-18. 10.1097/00008571-200401000-00001.PubMedGoogle Scholar
- 135.Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, Cherrington NJ: Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug metabolism and disposition: the biological fate of chemicals. 2009, 37 (10): 2087-2094. 10.1124/dmd.109.027466.Google Scholar
- 136.Bains RK: African variation at Cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases. Evolution, medicine, and public health. 2013, 118-134. 1Google Scholar
- 138.Fleeman N, Dundar Y, Dickson R, Jorgensen A, Pushpakom S, McLeod C, Pirmohamed M, Walley T: Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. The pharmacogenomics journal. 2011, 11 (1): 1-14. 10.1038/tpj.2010.73.PubMedGoogle Scholar
- 141.Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J: Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clinical pharmacokinetics. 2005, 44 (12): 1209-1225. 10.2165/00003088-200544120-00002.PubMedGoogle Scholar
- 142.Holstein A, Beil W, Kovacs P: CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert opinion on drug metabolism & toxicology. 2012, 8 (12): 1549-1563. 10.1517/17425255.2012.722619.Google Scholar
- 143.Mirghani RA, Chowdhary G, Elghazali G: Distribution of the major cytochrome P450 (CYP) 2C9 genetic variants in a Saudi population. Basic & clinical pharmacology & toxicology. 2011, 109 (2): 111-114. 10.1111/j.1742-7843.2011.00692.x.Google Scholar
- 144.Dai DP, Wang SH, Geng PW, Hu GX, Cai JP: In Vitro Assessment of 36 CYP2C9 Allelic Isoforms found in the Chinese Population on the Metabolism of Glimepiride. Basic & clinical pharmacology & toxicology. 2013Google Scholar
- 146.Zhang X, Li L, Ding X, Kaminsky LS: Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug metabolism and disposition: the biological fate of chemicals. 2011, 39 (8): 1433-1439. 10.1124/dmd.111.038836.Google Scholar
- 148.Alzahrani AM, Ragia G, Hanieh H, Manolopoulos VG: Genotyping of CYP2C9 and VKORC1 in the Arabic population of Al-Ahsa, Saudi Arabia. BioMed research international. 2013, 315980Google Scholar
- 149.Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS, Mizugaki M: Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. British journal of clinical pharmacology. 2002, 53 (6): 596-603. 10.1046/j.1365-2125.2002.01604.x.PubMedPubMedCentralGoogle Scholar
- 159.Moore CB, Wallace JR, Frase AT, Pendergrass SA, Ritchie MD: Using BioBin to explore rare variant population stratification. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing. 2013, 332-343.Google Scholar
- 163.Ibrahim NK, Al-Bar H, Al-Fakeeh A, Al Ahmadi J, Qadi M, Al-Bar A, Milaat W: An educational program about premarital screening for unmarried female students in King Abdul-Aziz University, Jeddah. Journal of infection and public health. 2011, 4 (1): 30-40. 10.1016/j.jiph.2010.11.001.PubMedGoogle Scholar
- 165.McBride MS: Bioinformatics and Intellectual Property Protection. Berkeley technology law journal. 2002, 17 (4): 1331-1334.Google Scholar
- 167.D'Souza S: Gene meets machine: intellectual property issues in bioinformatics. Health Law Review. 2004, 12 (2): 34-43.Google Scholar
- 169.Ogbogu U, Burningham S, Ollenberger A, Calder K, Du L, El Emam K, Hyde-Lay R, Isasi R, Joly Y, Kerr I, et al: Policy recommendations for addressing privacy challenges associated with cell-based research and interventions. BMC medical ethics. 2014, 15: 7-10.1186/1472-6939-15-7.PubMedPubMedCentralGoogle Scholar
- 171.Bowdin S, Ray P, Cohn RD, Meyn MS: The Genome Clinic: A Multidisciplinary Approach to Assessing the Opportunities and Challenges of Integrating Genomic Analysis Into Clinical Care. Human mutation. 2014Google Scholar
- 179.JAMAL TS, DAGHISTANI KJ, ZAKZOUK SS: Impact of Consanguinity on Childhood Hearing Impairment in a Saudi Population. J KAU: Med Sci. 2002, 10: 23-31.Google Scholar
- 180.Al-Qahtani MH, Baghlab I, Chaudhary AG, Abuzenadah AM, Bamanie A, Daghistani KJ, Safieh M, Fida L, Dallol A: Spectrum of GJB2 mutations in a cohort of nonsyndromic hearing loss cases from the Kingdom of Saudi Arabia. Genetic testing and molecular biomarkers. 2010, 14 (1): 79-83. 10.1089/gtmb.2009.0111.PubMedGoogle Scholar
- 185.Alhamdan NA, Almazrou YY, Alswaidi FM, Choudhry AJ: Premarital screening for thalassemia and sickle cell disease in Saudi Arabia. Genetics in medicine : official journal of the American College of Medical Genetics. 2007, 9 (6): 372-377. 10.1097/GIM.0b013e318065a9e8.Google Scholar
- 186.Akhtar MS, Qaw F, Borgio JF, Albuali W, Suliman A, Nasserullah Z, Al-Jarrash S, Al-Ali A: Spectrum of alpha-thalassemia mutations in transfusion-dependent beta-thalassemia patients from the Eastern Province of Saudi Arabia. Hemoglobin. 2013, 37 (1): 65-73. 10.3109/03630269.2012.753510.PubMedGoogle Scholar
- 187.Memish ZA, Owaidah TM, Saeedi MY: Marked regional variations in the prevalence of sickle cell disease and beta-thalassemia in Saudi Arabia: findings from the premarital screening and genetic counseling program. Journal of epidemiology and global health. 2011, 1 (1): 61-68. 10.1016/j.jegh.2011.06.002.PubMedGoogle Scholar
- 188.Abuzenadah AM, Hussein IM, Damanhouri GA, FM AS, Gari MA, Chaudhary AG, Zaher GF, Al-Attas A, Al-Qahtani MH: Molecular basis of beta-thalassemia in the western province of Saudi Arabia: identification of rare beta-thalassemia mutations. Hemoglobin. 2011, 35 (4): 346-357. 10.3109/03630269.2011.588508.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.